The FDA has approved Symproic (naldemedine) 0.2 mg oral tablets for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
As opioids are commonly prescribed in workers’ compensation for the treatment of pain, opioid-induced constipation is a common side effect found in injured worker populations, and so Symproic could be seen in future claims.
The ingredient naldemedine is a derivative of naltrexone, which is currently a Schedule II controlled substance, and therefore Symproic is also a Schedule II substance. A scheduling recommendation has been sent to the DEA in the hopes of changing the schedule of Symproic.
For more information, read the FDA’s approval letter.